NASDAQ:PLUR Pluri (PLUR) Stock Price, News & Analysis $5.14 -0.04 (-0.68%) As of 12:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Pluri Stock (NASDAQ:PLUR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pluri alerts:Sign Up Key Stats Today's Range$5.17▼$5.1750-Day Range$3.96▼$5.7952-Week Range$3.33▼$7.13Volume10,378 shsAverage Volume20,785 shsMarket Capitalization$40.41 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingBuy Company Overview Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel. Read More Pluri Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks44th Percentile Overall ScorePLUR MarketRank™: Pluri scored higher than 44% of companies evaluated by MarketBeat, and ranked 649th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPluri has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoveragePluri has only been the subject of 1 research reports in the past 90 days.Read more about Pluri's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Pluri is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pluri is -0.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPluri has a P/B Ratio of 5.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Pluri's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.77% of the float of Pluri has been sold short.Short Interest Ratio / Days to CoverPluri has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pluri has recently increased by 23.98%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPluri does not currently pay a dividend.Dividend GrowthPluri does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.77% of the float of Pluri has been sold short.Short Interest Ratio / Days to CoverPluri has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pluri has recently increased by 23.98%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.63 News SentimentPluri has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Pluri this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for PLUR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Pluri to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Pluri insiders have not sold or bought any company stock.Percentage Held by Insiders25.93% of the stock of Pluri is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.59% of the stock of Pluri is held by institutions.Read more about Pluri's insider trading history. Receive PLUR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pluri and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PLUR Stock News HeadlinesReviewing Pluri (NASDAQ:PLUR) and Medicus Pharma (NASDAQ:MDCX)August 26 at 3:27 AM | americanbankingnews.comPluri Inc. director not re-elected, Nasdaq compliance cure period grantedJuly 5, 2025 | investing.comHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.August 29 at 2:00 AM | The Oxford Club (Ad)Alliance Global Partners Initiates Coverage of Pluri (PLUR) with Buy RecommendationJune 2, 2025 | msn.comPluri Inc. reschedules 2025 annual meetingMay 27, 2025 | investing.comBrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical TrialsMay 27, 2025 | prnewswire.comBrainstorm Cell Therapeutics outlines imminent Phase 3b ALS trial launch following FDA clearance and expanded manufacturing plansMay 19, 2025 | msn.comPluri Inc.: Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.May 16, 2025 | finanznachrichten.deSee More Headlines PLUR Stock Analysis - Frequently Asked Questions How have PLUR shares performed this year? Pluri's stock was trading at $4.28 on January 1st, 2025. Since then, PLUR stock has increased by 20.0% and is now trading at $5.1350. How were Pluri's earnings last quarter? Pluri Inc. (NASDAQ:PLUR) posted its earnings results on Tuesday, May, 13th. The company reported ($0.94) earnings per share (EPS) for the quarter. The firm earned $0.43 million during the quarter. Pluri had a negative trailing twelve-month return on equity of 4,191.91% and a negative net margin of 2,563.29%. When did Pluri's stock split? Pluri shares reverse split before market open on Monday, April 1st 2024.The 1-8 reverse split was announced on Monday, April 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. How do I buy shares of Pluri? Shares of PLUR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Pluri own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pluri investors own include Digital Turbine (APPS), Lightning eMotors (ZEV), Archer Aviation (ACHR), ChargePoint (CHPT) and Canoo (GOEV). Company Calendar Last Earnings5/13/2025Today8/29/2025Next Earnings (Estimated)9/17/2025Fiscal Year End6/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PLUR CIK1158780 Webpluri-biotech.com Phone972747108600Fax972-74-710-8787Employees150Year FoundedN/APrice Target and Rating Average Price Target for Pluri$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+133.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($5.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$20.89 million Net Margins-2,563.29% Pretax Margin-1,789.02% Return on Equity-4,191.91% Return on Assets-85.40% Debt Debt-to-Equity Ratio51.65 Current Ratio4.81 Quick Ratio4.81 Sales & Book Value Annual Sales$330 thousand Price / Sales122.46 Cash FlowN/A Price / Cash FlowN/A Book Value$1.00 per share Price / Book5.14Miscellaneous Outstanding Shares7,870,000Free Float5,830,000Market Cap$40.41 million OptionableOptionable Beta0.76 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:PLUR) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.